PR Newswire
GAITHERSBURG, Md., Nov. 10, 2023
GAITHERSBURG, Md., Nov. 10, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-Mâ„¢ adjuvant, today announced that it will participate in the Jefferies London Healthcare Conference.
Conference Details: | |||||
Fireside Chat | |||||
Date: | Wednesday, November 15, 2023 | ||||
Time: | 9:00 – 9:25 a.m. Greenwich Mean Time (GMT) | ||||
Location: | London | ||||
Moderator: | Roger Song, M.D., CFA, Equity Analyst | ||||
Novavax participants: | John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research & Development | ||||
Conference | |||||
Event: | Investor Meetings | ||||
Date: | Wednesday, November 15, 2023 | ||||
Recordings
A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 45 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
[email protected]
Media
Ali Chartan
240-720-7804
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-jefferies-london-healthcare-conference-301984205.html
SOURCE NOVAVAX, INC
